Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: A meta-analysis revisited

Clinical Medicine and Research

Volumn 5, Issue 2, 2007, Pages 87-90

  Doi, Suhail A R ^a   Woodhouse, Nicholas J ^b   Thalib, Lukman ^a   Onitilo, Adedayo ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c MARSHFIELD CLINIC   (United States)

Author keywords

Meta analysis; Postoperative ablation; Radioiodine; Recurrence; Thyroglobulin; Thyroid cancer

Indexed keywords

IODINE 131; THYROGLOBULIN; TUMOR MARKER; RADIOACTIVE IODINE;

ARTICLE; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THYROID ABLATION; THYROID CANCER; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; CELL DIFFERENTIATION; MORTALITY; PAPILLARY CARCINOMA; PATHOLOGY; RADIATION DOSE; REVIEW; RISK FACTOR; THYROID TUMOR; TUMOR RECURRENCE;

CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; HUMANS; IODINE RADIOISOTOPES; META-ANALYSIS AS TOPIC; NEOPLASM RECURRENCE, LOCAL; RADIATION DOSAGE; RISK FACTORS; THYROID NEOPLASMS;

EID: 37349049936     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2007.763     Document Type: Article

References (28)

1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
2. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14:1063-1075.
3. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
4. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 1990;19:741-760.
5. Pagano L, Klain M, Pulcrano M, Angellotti G, Pasano F, Salvatore M, Lombardi G, Biondi B. Follow-up of differentiated thyroid carcinoma. Minerva Endocrinol 2004;29:161-174.
6. Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005;152:33-37.
7. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000;52:765-773.
8. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007;92:28-38.
9. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987;12:500-502.
10. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991;32:252-254.
11. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77:2574-2580.
12. Gawkowska-Suwinska M, Turska M, Roskosz J, Puch Z, Jurecka-Tuleja B, Handkiewicz-Junak D, Wygoda Z, Jarzab B. Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer. Wiad Lek 2001;54:278-288.
13. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004;89:1666-1673.
14. Sirisalipoch S, Buachum V, Pasawang P, Tepmongkol S. Prospective randomised trial for the evaluation of the efficacy of low vs high dose I-131 for post-operative remnant ablation in differentiated thyroid cancer. World J Nuclear Med 2004; 3:S36 [Abstract].
15. Rosario PW, Reis JS, Barroso AL, Rezende LL, Padrao EL, Fagundes TA. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Nucl Med Commun 2004;25:1077-1081.
16. Ramanna L, Waxman AD, Brachman MB, Tanasescu DE, Sensel N, Braunstein GD. Evaluation of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1985;10:791-795.
17. Verkooijen RB, Stokkel MP, Smit JW, Pauwels EK. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med Mol Imaging 2004;31:499-506.
18. Hodgson DC, Brierley JD, Tsang RW, Panzarella T. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol 1998;47:325-330.
19. Angelini F, Capezzone M, Cecarelli C, Lippi F. Comparison among different 1311 activities for ablation of post-surgical thyroid residues. In: Hennemann G, ed. Thyroid International, Report of the 24th annual meeting of the European Thyroid Association. Darmstudt, Germany: Merck KgaA, No. 6-1997.
20. Zidan J, Hefer E, Iosilevski G, Drumea K, Stein ME, Kuten A, Israel O. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer. Int J Radiat Oncol Biol Phys 2004;59:1330-1336.
21. Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD. Radioiodine-131 therapy for well-differentiated thyroid cancer - a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33:1132-1136.
22. Logue JP, Tsang RW, Brierley JD, Simpson WJ. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol 1994;67:1127-1131.
23. Liu RT, Huang MJ, Huang HS, Huang BY, Lin JD, Wang PW, Tzen KY. Comparison of 30mCi and higher doses of iodine-131 for postoperative thyroid remnant ablation. Taiwan Yi Xue Hui Za Zhi 1987;86:524-528.
24. Lin JD, Kao PF, Chao TC. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol 1998;71:307-313.
25. Ramacciotti C, Pretorius HT, Line BR, Goldman JM, Robbins J. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: concise communication. J Nucl Med 1982;23:483-489.
26. McCowen KD, Adler RA, Ghaed N, Verdon T, Hofeldt FD. Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 1976;61:52-58.
27. Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol 1998;21:77-81.
28. Degroot LJ, Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1982;96:51-53.